Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire)
Related: Campus Connections
Chapel Hill businesses thrive as Mexico vs. Türkiye soccer game brings thousands to townMore than 25,000 fans gathered in Chapel Hill to watch Mexico’s and Türkiye’s national men’s soccer teams at Kenan Stadium. Vincenzo Marrone, the co-owner of...
Mon Jun 23, 2025Longest-running fraternity at UNC shut down by national board
The longest-running fraternity at UNC-Chapel Hill has been shut down by its national office, university officials said Thursday. The UNC chapter of Alpha Tau Omega...
Fri Jun 20, 2025
UNC Alumnus Killed in Minnesota Assassination
Mark Hortman, the husband of slain Minnesota lawmaker Melissa Hortman, was killed alongside his wife in a targeted attack at their home Saturday. Mark Hortman,...
Fri Jun 20, 2025
36 Hours in Chapel Hill: A Perfect Weekend Itinerary of Food, Fun & Local Charm
We’ve explored just about every corner of the Triangle, but Chapel Hill always gives us new reasons to fall in love. With its perfect blend...
Wed Jun 18, 2025